Zealand presents at three international biotech/healthcare investor conferences in November and December 2016

COPENHAGEN, Nov. 10, 2016 -- Investor News - No. 8 / 2016

Zealand informs that its management will present the company and host investor meetings at the following healthcare and biotech investor forums in November and December 2016, taking place in Paris, London and New York, respectively.

Bryan Garnier & Co. Annual Healthcare Conference, Paris - 15 November 2016

Zealand will host one-to-one investor meetings. Britt Meelby Jensen, President and CEO and Mats Blom, Senior Vice President and CFO will represent the company.

Jefferies 2016 Healthcare Conference, London - 16 November 2016

Zealand will host one-to-one meetings. Britt Meelby Jensen, President and CEO and Mats Blom, Senior Vice President and CFO will represent the company.

Citi 2016 Global Healthcare Conference, New York - 7 December 2016

Zealand will host one-to-one investor meetings. Britt Meelby Jensen, President and CEO and Mats Blom, Senior Vice President and CFO will represent the company.

Please note that no new financial or other material information relating to Zealand and its business will be disclosed at these meetings.

*****

For further information, please contact:

Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, email: [email protected]

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn and a pipeline of proprietary product candidates, which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia^® outside the United States and approved as Adlyxin^TM in the United States. Lixisenatide has been developed in a fixed-ratio combination with Lantus^® (insulin glargine) which product is under regulatory review in the United States and in Europe. 

Zealand's proprietary pipeline includes: Dasiglucagon^* (ZP4207) as single-dose rescue treatment for acute, severe hypoglycemia (Phase II); Glepaglutide* (ZP1848) for treatment of short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN)

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/1f25f8e8-7b13-4f62-b6bf-ed6e48525ca9